| Document info |
|---|
| Organization | AXA |
|---|
| Year | 2026 |
|---|
| Period | 1Q |
|---|
| Period label | 1Q26 |
|---|
| Document type | Earnings press release |
|---|
| Publication date | 2026-05-05 |
|---|
| Market timing | Pre-market |
|---|
| Language | English |
|---|
| Pages | 16 |
|---|
| Source | Original URL |
|---|
| Archive | .md file |
|---|
This article summarizes AXA's first quarter 2026 earnings press release, published on May 5, 2026.
1Q26 highlights
- Gross written premiums & other revenues +6% vs. 1Q25 to EUR 38.0bn p. 1
- Property & Casualty premiums +4% to EUR 21.5bn p. 1
- Retail premiums +7% (+4% from price effect, +3% from volumes) p. 1
- Commercial premiums +3% (equal contributions from price effect and volumes) p. 1
- Life & Health premiums +8% to EUR 16.5bn p. 1
- Life premiums +8% p. 1
- Health premiums +8% p. 1
- Life & Health NB CSM +4% p. 1
- Net flows of EUR +2.7bn p. 1
- Solvency II ratio at 211% as of March 31, 2026, -4 points vs. January 1, 2026 (post-grandfathering period) p. 1
Outlook 3
- AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range p. 1
- AXA will present its new strategic plan for 2027-2029 on September 15, 2026 p. 1
- > "AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy," — Alban de Mailly Nesle, Chief Financial Officer of AXA p. 1
- This performance highlights the continued robust expansion of P&C businesses in both Retail and Commercial, with growth balanced between pricing and volumes p. 1
- Life & Health revenues reflect the continuation of strong momentum from the previous year p. 1
- > "In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." p. 1
- > "I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." p. 1
Press release
- The 1Q26 activity indicators were released on May 5, 2026 (5:45pm CET) p. 1
- The activity indicators show sustained revenue momentum p. 1
1Q26 key highlights
Key financial figures for 1Q25 and 1Q26, including changes in USD and LFL. p. 2
| Key figures
|
1Q25
|
1Q26
|
Change USD
|
Change LFL
|
| Gross written premiums and other revenues
|
37.0
|
38.0
|
+3%
|
+6%
|
| o/w Property & Casualty
|
21.0
|
21.5
|
+2%
|
+4%
|
| o/w Life & Health
|
15.5
|
16.5
|
+7%
|
+8%
|
| o/w Asset Management
|
0.4
|
n.m.
|
n.m.
|
n.m.
|
Solvency II ratio for FY25, January 1, 2026, and 1Q26, with changes. p. 2
| Key figures (in Euro billion, unless otherwise noted)
|
FY25
|
January 1, 2026
|
1Q26
|
Change vs. January 1, 2026
|
| Solvency II ratio (%)
|
224%
|
215%
|
211%
|
-4pts
|
Activity indicators
- Total gross written premiums & other revenues were +6% p. 2
- Property & Casualty +4% p. 2
- Personal lines +7%, driven by higher volumes and favorable price effect p. 2
- Commercial lines (excluding AXA XL Reinsurance) +3%, from higher volumes (notably at AXA XL Insurance) and favorable price effect, mainly in SME & Mid-market business in Europe and France p. 2
- AXA XL Reinsurance -7%, reflecting discipline in softening market conditions p. 2
- Life & Health +8% p. 2
- Life premiums +8%, driven by strong sales in Unit-Linked (+16%) and G/A (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan p. 2
- Health premiums +8%, driven by favorable price effects across all geographies p. 2
- Solvency II ratio was 211% as of March 31, 2026 p. 2
- On January 1, 2026, the Solvency II ratio was 215% following the end of the grandfathering period (-10 points vs. December 31, 2025) p. 2
- The Solvency II ratio decreased by -4 points vs. January 1, 2026, due to: p. 2
- Strong operating return (+7 points) p. 2
- Less accrued dividend and annual share buyback for 1Q26 (-6 points) p. 2
- Unfavorable financial market movements (-4 points), notably from higher inflation expectations and elevated equity and interest rate volatility p. 2
Property & Casualty
Property & Casualty key figures for 1Q25 and 1Q26, including price effect. p. 3
| Key figures
|
1Q25
|
1Q26
|
Change LFL
|
1Q26 Price effect (in %)
|
| Gross written premiums and other revenues
|
21.0
|
21.5
|
+4%
|
+1.9%
|
| o/w Commercial lines
|
13.2
|
13.2
|
+3%
|
+1.5%
|
| o/w Personal lines
|
6.4
|
7.0
|
+7%
|
+4.0%
|
| o/w AXA XL Reinsurance
|
1.4
|
1.2
|
-7%
|
-3.9%
|
- Gross written premiums & other revenues for P&C were +4% to EUR 21.5bn p. 3
- Personal lines grew by 7% to EUR 7.0bn, driven by: p. 3
- Europe (+7%), from favorable price effects across geographies (except UK & Ireland) and higher volumes p. 3
- France (+8%), with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect p. 3
- Asia, Africa & EME LATAM (+7%), mainly driven by higher average premiums in Türkiye and higher volumes in Mexico p. 3
- Commercial lines grew by 3% to EUR 13.2bn, mainly from: p. 3
- AXA XL Insurance (+2%), from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing remains stable vs. 1Q25 p. 3
- France (+6%), from both favorable price effect and higher volumes p. 3
- Asia, Africa & EME-LATAM (+10%), mainly driven by higher average premiums in Türkiye p. 3
- AXA XL Reinsurance decreased by 7% to EUR 1.2bn, reflecting lower volumes consistent with focus on profitability in a softer market environment, with pricing down -4% p. 3
- Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget p. 3
- The annual natural catastrophe budget of approximately 4.5 points of combined ratio is maintained p. 3
Life & Health
Life & Health key figures for 1Q25 and 1Q26, including PVEP, NB CSM, and NBV. p. 4
| Key figures
|
1Q25
|
1Q25 Updated*
|
1Q26
|
Change vs. 1Q25 updated LFL
|
| Gross written premiums and other revenues
|
15.5
|
—
|
16.5
|
+8%
|
| o/w Life
|
9.8
|
—
|
10.5
|
+8%
|
| o/w Health
|
5.6
|
—
|
5.9
|
+8%
|
| PVEP
|
13.7
|
13.0
|
13.8
|
+8%
|
| NB CSM (pre-tax)
|
0.6
|
0.6
|
0.6
|
+4%
|
| NBV (post-tax)
|
0.7
|
0.6
|
0.6
|
+1%
|
| NBV margin
|
4.9%
|
4.8%
|
4.4%
|
-0.3pt
|
- 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability p. 4
- All year-on-year changes are on a comparable basis vs. the updated 1Q25 figures p. 4
- Gross written premiums & other revenues were +8% to EUR 16.5bn p. 4
- Life premiums increased by 8% to EUR 10.5bn, driven by: p. 4
- Unit-Linked (+16%), from continued positive sales momentum across geographies p. 4
- G/A Savings (+9%), mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland p. 4
- Protection (+4%), primarily from continued success of Protection with G/A savings in Hong Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland p. 4
- Health premiums increased by 8% to EUR 5.9bn, driven by favorable price effects across all geographies p. 4
- PVEP (Present Value of Expected Premiums) was +8% to EUR 13.8bn, driven by: p. 4
- Life (+10%), reflecting strong sales across geographies in both Savings (+14%) and Protection (+6%), partly offset by lower Group Life sales in Switzerland p. 4
- Health (+4%), mainly due to higher Group business volumes in France, partly offset by Japan p. 4
- NB CSM (pre-tax) increased by 4% to EUR 0.6bn, driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix (including lower Group Life sales in Switzerland and Health sales in Japan) p. 4
- NBV (post-tax) was +1% to EUR 0.6bn, as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China p. 4
- NBV margin decreased by 0.3 point to 4.4% p. 4
- Net flows were EUR +2.7bn, compared to EUR +2.5bn in 1Q25, driven by: p. 4
- Protection (EUR +1.8bn), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product p. 4
- Unit-Linked (EUR +0.7bn), primarily in France p. 4
- G/A Savings (EUR -0.8bn), reflecting inflows in capital-light G/A savings (EUR +0.7bn) more than offset by outflows in traditional G/A Savings (EUR -1.5bn) p. 4
- Health (EUR +1.0bn), mostly from Germany, France and Japan p. 4
Ratings
Insurer financial strength and credit ratings from S&P, Moody's, and AM Best. p. 5
| —
|
—
|
Insurer financial strength ratings
|
Insurer financial strength ratings
|
Insurer financial strength ratings
|
AXA's credit ratings
|
AXA's credit ratings
|
| S&P Global Ratings
|
March 11, 2026
|
AA-
|
AA
|
Stable
|
AA-
|
A-1+
|
| Moody's Investor Service
|
October 8, 2025
|
Aa2
|
Aa2
|
Stable
|
Aa3
|
P-1
|
| AM Best
|
October 9, 2025
|
A+ Superior
|
—
|
Stable
|
aa Superior
|
—
|
Glossary
- Capital-light G/A products encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% p. 5
- Contractual service margin ('CSM') is a component of the carrying amount of the asset or liability for a group of insurance contracts, representing the unearned profit to be recognized as services are provided to policyholders p. 5
- Gross written premiums and other revenues include insurance premiums collected (risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions on assumed reinsurance) and premiums/fees from non-insurance activities (banking, services, asset management) p. 5
- New business contractual service margin ('NB CSM') is a component of the carrying amount for newly issued insurance contracts, representing the unearned profit to be recognized as services are provided p. 5
- New business value ('NBV') is the value of newly issued contracts during the current year, comprising NB CSM, present value of future profits of Short-Term Business (Life entities, considering renewals), present value of future profits of pure investment contracts (IFRS 9), net of reinsurance cost, taxes, and minority interests p. 5
- New business value margin ('NBV Margin') is the ratio of NBV to PVEP p. 5
- Present value of expected premiums ('PVEP') is the new business volume, equal to the present value at issue of total premiums expected over the policy term, discounted at the reference interest rate, and is Group share p. 5
- AM: AM Best
- AMF: Autorité des Marchés Financiers
- APM: Alternative Performance Measure
- CLP: Credit and Lifestyle Protection
- CSM: Contractual Service Margin
- DJSI: Dow Jones Sustainability Index
- DPF: Discretionary Participation Features
- EME: Emerging Markets Europe
- ESMA: European Securities and Markets Authority
- GWP: Gross Written Premiums
- IFRS: International Financial Reporting Standards
- LATAM: Latin America
- LFL: Like-for-Like
- NB CSM: New Business Contractual Service Margin
- NBV: New Business Value
- OTC QX: Over The Counter QX
- PVEP: Present Value of Expected Premiums
- SFCR: Solvency and Financial Condition Report
- SME: Small and Medium-sized Enterprises
- SRI: Socially Responsible Investment
- UEPS: Underlying Earnings Per Share
- UN: United Nations
- UNEP FI: United Nations Environment Programme's Finance Initiative
Scope
- France includes insurance activities, banking activities, and holding p. 6
- Europe includes Switzerland (insurance), Germany (insurance and holding), Belgium and Luxemburg (insurance and holding), UK and Ireland (insurance and holding), Spain (insurance and holding), Italy (insurance), Prima (insurance), AXA Health International (insurance), and AXA Life Europe (insurance) p. 6
- AXA XL includes insurance and reinsurance activities and holding p. 6
- Asia, Africa & EME-LATAM includes: p. 6
- Asia: Japan (insurance and holding), Hong Kong (insurance), Thailand P&C, Indonesia L&S (excl. bancassurance), China P&C, South Korea, and Asia Holdings (fully consolidated); China L&S, Thailand L&S, Philippines L&S and P&C, Indonesia L&S (bancassurance) (equity method, contributing only to NBV, PVEP, underlying earnings, and net income) p. 6
- Africa: Egypt (insurance and holding), Morocco (insurance and holding), and Nigeria (insurance and holding) (fully consolidated) p. 6
- EME-LATAM: Mexico (insurance), Colombia (insurance), Brazil (insurance and holding), and Türkiye (insurance and holding) (fully consolidated); Russia (Reso) (insurance) (equity method, contributing only to net income) p. 6
- AXA Mediterranean Holdings p. 6
- Transversal & Other includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (including Group's internal reinsurance activity), and other Central Holdings p. 6
- AXA Investment Managers' disposal to BNP Paribas was completed on July 1, 2025 p. 6
Exchange rates
End of period and average exchange rates for various currencies against the Euro. p. 6
| For 1 Euro
|
End of Period Exchange rate
|
End of Period Exchange rate
|
Average Exchange rate
|
Average Exchange rate
|
| USD
|
1.17
|
1.15
|
1.05
|
1.17
|
| CHF
|
0.93
|
0.93
|
0.95
|
0.92
|
| GBP
|
0.87
|
0.87
|
0.84
|
0.87
|
| JPY
|
184
|
183
|
160
|
184
|
| HKD
|
9.14
|
9.03
|
8.19
|
9.14
|
Notes
- Changes in gross written premiums & other revenues, NBV, PVEP, and NBV Margin are on a comparable basis (constant forex, scope, and methodology) unless otherwise indicated p. 7
- These terms are defined in the glossary section of the press release p. 7
- The Solvency II ratio is estimated using AXA's internal model, calibrated based on an adverse 1/200 years shock p. 7
- It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of EUR 2.32 per share for FY25 and an annual share buyback of EUR 1.25bn announced on February 26, 2026 p. 7
- Annual share buybacks exclude anti-dilutive buybacks related to disposals and in-force management, and buybacks to offset dilutive effects from employee share offerings and stock-based compensation p. 7
- Dividends and share buybacks are proposed by the Board and submitted to shareholders for approval p. 7
- This estimate is not an indication of actual dividend and share buyback amounts for FY26 p. 7
- For more information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, on www.axa.com p. 7
- The underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement providing one-off guidance for the last year of the current strategic plan p. 7
- 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance p. 7
- Price effect is calculated as a percentage of total gross written premiums of the prior year p. 7
- G/A refers to General Account p. 7
- Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, after which they ceased to qualify as capital under Solvency II p. 7
- Natural catastrophe charges include natural catastrophe losses regardless of event size p. 7
- Combined ratio is a non-GAAP financial measure (Alternative Performance Measure or APM) p. 7
- Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities p. 7
- Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's p. 7
- Tier 2 is rated 'A' by Standard & Poor's and 'A (hyb)' by Moody's p. 7
- AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 p. 7
- All comments and changes for activity indicators are on a comparable basis (constant forex, scope, and methodology) p. 7
- Actuarial and financial assumptions for NBV and PVEP are updated semi-annually at half year and full year p. 7
- Financial figures and information in this press release have not been audited or subject to limited review by AXA's statutory auditors p. 7
About the AXA Group
- AXA Group is a global insurance leader with 156,000 employees serving over 92 million clients in 52 countries p. 8.
- In 2025, AXA's revenues were EUR 115.5bn and underlying earnings were EUR 8.4bn p. 8.
- AXA's ordinary share is listed on compartment A of Euronext Paris under ticker symbol CS (ISN FR 0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA) p. 8.
- AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol AXAHY p. 8.
- AXA Group is included in major international SRI indexes, including Dow Jones Sustainability Index (DJSI) and FTSE4GOOD p. 8.
- AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment p. 8.
- This press release and regulated information are available on the AXA Group website (axa.com) p. 8.
- Forward-looking statements in the press release, including expected underlying earnings per share (UEPS) growth for 2026, are based on Management's current views and intentions and are subject to change p. 8.
- Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially p. 8.
- AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by law p. 8.
- Non-GAAP financial measures (APMs) are used by Management for analyzing operating trends, financial performance, and position, and may not be comparable to measures used by other companies p. 8.
- APMs should not be considered in isolation from or as a substitute for the Group's consolidated financial statements prepared in accordance with IFRS p. 8.
- "Underlying earnings", UEPS, "underlying return on equity", "combined ratio", and "debt gearing" are APMs as defined in ESMA's guidelines and AMF's position statement issued in 2015 p. 8.
- Reconciliations of APMs to IFRS financial statements are provided in the 2025 Universal Registration Document, Section 2.3.3 'Alternative Performance Measures' p. 8.
- Investor Relations can be reached at +33.1.40.75.48.42 or investor.relations@axa.com p. 8.
- Individual Shareholder Relations can be reached at +33.1.40.75.48.43 p. 8.
- Media Relations can be reached at +33.1.40.75.46.74 or ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com p. 8.
- Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments p. 8.
- SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes p. 8.
Gross written premiums by region and business line for 1Q25 and 1Q26. p. 9
| in Euro million
|
GWP 1Q25 Published
|
GWP 1Q25 Adjusted ii,iii
|
GWP 1Q26
|
GWP Change USD vs. 1Q25 Adjusted
|
GWP Change LFL
|
o/w P&C 1Q26
|
o/w P&C Change LFL
|
o/w Life & Health 1Q26
|
o/w Life & Health Change LFL
|
| France
|
8,440
|
7,923
|
8,393
|
+6%
|
+5%
|
3,355
|
+6%
|
5,012
|
+4%
|
| Europe iii
|
15,289
|
15,608
|
16,905
|
+8%
|
+6%
|
9,328
|
+4%
|
7,577
|
+9%
|
| AXA XL
|
6,984
|
6,984
|
6,488
|
-7%
|
0%
|
6,459
|
0%
|
29
|
-1%
|
| Asia, Africa & EME-LATAM
|
5,286
|
5,286
|
5,403
|
+2%
|
+11%
|
1,719
|
+8%
|
3,684
|
+13%
|
| Transversal ii
|
525
|
723
|
764
|
+6%
|
+6%
|
601
|
+8%
|
163
|
-2%
|
| AXA Investment Managers
|
443
|
443
|
—
|
n.m.
|
n.m.
|
—
|
—
|
—
|
—
|
| Total i
|
36,967
|
36,967
|
37,953
|
+3%
|
+6%
|
21,462
|
+4%
|
16,464
|
+8%
|
- Banking revenues were EUR 26m in 1Q26 and EUR 25m in 1Q25 p. 9.
- Portfolio of lifestyle and income protection (CLP) premiums were reallocated from France to Transversal p. 9.
- CLP premiums in 1Q25 were EUR 198m, with EUR 68m in P&C and EUR 130m in Life & Health p. 9.
- CLP premiums in 1Q26 were EUR 201m, with EUR 68m in P&C and EUR 132m in Life & Health p. 9.
- International protection and health premiums previously recorded in AXA France are now reported under the new carrier AXA Health International, which is part of Europe p. 9.
- These premiums were EUR 319m in 1Q25, with EUR 104m in Life and EUR 215m in Health p. 9.
- These premiums were EUR 336m in 1Q26, with EUR 103m in Life and EUR 233m in Health p. 9.
Gross written premiums for Commercial, Personal, and Reinsurance lines by region. p. 10
|
|
Commercial lines
|
Personal lines
|
AXA XL Reinsurance
|
Total P&C
|
| in Euro million
|
Total Commercial
|
Change i
|
Personal Motor
|
Change i
|
Personal Non-Motor
|
Change i
|
Total Personal
|
Change
|
Total Reinsurance
|
Change i
|
1Q26
|
Change
|
| France
|
2,061
|
+6%
|
766
|
+10%
|
528
|
+4%
|
1,294
|
+8%
|
—
|
—
|
3,355
|
+6%
|
| Europe
|
4,388
|
+1%
|
3,370
|
+10%
|
1,570
|
+2%
|
4,940
|
+7%
|
—
|
—
|
9,328
|
+4%
|
| AXA XL
|
5,215
|
+2%
|
—
|
—
|
—
|
—
|
—
|
—
|
1,244
|
-7%
|
6,459
|
0%
|
| Asia, Africa & EME-LATAM
|
952
|
+10%
|
577
|
+8%
|
190
|
+2%
|
767
|
+7%
|
—
|
—
|
1,719
|
+8%
|
| Transversal
|
601
|
+8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
601
|
+8%
|
| Total
|
13,217
|
+3%
|
4,712
|
+9%
|
2,288
|
+2%
|
7,001
|
+7%
|
1,244
|
-7%
|
21,462
|
+4%
|
- Changes are presented on a comparable basis (constant forex, scope, and methodology) p. 10.
Exchange rates for various currencies against the Euro for FY25 and 1Q26. p. 10
| —
|
FY25 i
|
1Q26 ii
|
| EUR
|
2.6%
|
2.7%
|
| USD
|
4.2%
|
4.0%
|
| JPY
|
1.0%
|
1.6%
|
| GBP
|
4.3%
|
4.2%
|
| CHF
|
0.2%
|
0.2%
|
| HKD
|
3.2%
|
2.8%
|
Property & Casualty price effect by country and business line for 1Q26. p. 11
| P&C: Price effect i by country and business line
|
| 1Q26 (in %)
|
Commercial lines
|
Personal lines
|
AXA XL Reinsurance
|
| France
|
+3.5%
|
+2.6%
|
—
|
| Europe
|
+3.0%
|
+4.2%
|
—
|
| Switzerland
|
+4.0%
|
+5.1%
|
—
|
| Germany
|
+2.5%
|
+4.2%
|
—
|
| Belgium & Luxembourg
|
+2.2%
|
+2.4%
|
—
|
| UK & Ireland
|
+0.5%
|
-0.9%
|
—
|
| Spain
|
+5.7%
|
+6.0%
|
—
|
| Italy
|
+2.7%
|
+3.8%
|
—
|
| AXA XL ii
|
-0.2%
|
—
|
-3.9%
|
| Asia, Africa & EME-LATAM
|
+0.4%
|
+5.6%
|
—
|
| Total
|
+1.5%
|
+4.0%
|
-3.9%
|
- [Chart/image description: A table titled "Interest Rates (5Y) For the Discounting of P&C Claims Reserves" shows the following data:
- Country: France, Germany, Italy, Spain, Switzerland, UK, US, Japan, Other Europe, Other Asia, Other
- 1Q26: 2.9%, 2.9%, 3.0%, 3.0%, 0.9%, 4.2%, 4.6%, 0.6%, 3.0%, 3.0%, 3.0%
- 1Q25: 2.7%, 2.7%, 2.8%, 2.8%, 0.8%, 4.0%, 4.4%, 0.5%, 2.8%, 2.8%, 2.8%
- Change (bps): +20, +20, +20, +20, +10, +20, +20, +10, +20, +20, +20] p. 12
- The 5-year interest rate for discounting P&C claims reserves in France was 2.9% in 1Q26, up 20bps from 2.7% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Germany was 2.9% in 1Q26, up 20bps from 2.7% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Italy was 3.0% in 1Q26, up 20bps from 2.8% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Spain was 3.0% in 1Q26, up 20bps from 2.8% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Switzerland was 0.9% in 1Q26, up 10bps from 0.8% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in the UK was 4.2% in 1Q26, up 20bps from 4.0% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in the US was 4.6% in 1Q26, up 20bps from 4.4% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Japan was 0.6% in 1Q26, up 10bps from 0.5% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Other Europe was 3.0% in 1Q26, up 20bps from 2.8% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Other Asia was 3.0% in 1Q26, up 20bps from 2.8% in 1Q25 p. 12.
- The 5-year interest rate for discounting P&C claims reserves in Other regions was 3.0% in 1Q26, up 20bps from 2.8% in 1Q25 p. 12.
Gross written premiums by business line and region, including protection and savings. p. 12
| GWP
|
Total i
|
o/w Protection
|
o/w G/A Savings
|
o/w Unit-Linked
|
o/w Health
|
| in Euro million
|
1Q26
|
Change ii
|
1Q26
|
Change ii
|
1Q26
|
Change ii
|
1Q26
|
Change ii
|
1Q26
|
Change ii
|
| France
|
5,012
|
+4%
|
996
|
+3%
|
1,325
|
+1%
|
1,437
|
+7%
|
1,253
|
+4%
|
| Europe
|
7,577
|
+9%
|
1,986
|
0%
|
1,263
|
+16%
|
1,044
|
+24%
|
3,283
|
+8%
|
| AXA XL
|
29
|
-1%
|
15
|
+1%
|
14
|
-2%
|
—
|
—
|
—
|
—
|
| Asia, Africa & EME-LATAM
|
3,684
|
+13%
|
1,764
|
+10%
|
319
|
+27%
|
224
|
+35%
|
1,377
|
+10%
|
| Transversal
|
163
|
-2%
|
132
|
-1%
|
—
|
—
|
—
|
—
|
31
|
-5%
|
| Total
|
16,464
|
+8%
|
4,893
|
+4%
|
2,922
|
+9%
|
2,705
|
+16%
|
5,944
|
+8%
|
| o/w short-term iii
|
5,436
|
+6%
|
1,183
|
+1%
|
—
|
—
|
—
|
—
|
4,253
|
+7%
|
- PVEP, NB CSM, NBV, and NBV margin for 1Q25, 1H25, and 9M25 have been updated based on FY25 actuarial and financial assumptions p. 13.
Updated 1Q25 figures for various regions and business lines. p. 13
| 1Q25 Updated figures
|
|
|
|
|
|
|
|
|
|
|
Total i
|
| in Euro million
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
| France ii,iii
|
3,026
|
94
|
103
|
3.4%
|
1,565
|
—
|
44
|
2.8%
|
4,591
|
94
|
147
|
3.2%
|
| Europe iii
|
2,982
|
183
|
161
|
5.4%
|
1,627
|
74
|
66
|
4.0%
|
4,609
|
257
|
227
|
4.9%
|
| Asia, Africa & EME-LATAM
|
3,128
|
178
|
185
|
5.9%
|
612
|
67
|
61
|
9.9%
|
3,740
|
245
|
246
|
6.6%
|
| Transversal ii
|
63
|
5
|
3
|
5.2%
|
—
|
—
|
—
|
—
|
63
|
5
|
3
|
5.2%
|
| Total
|
9,199
|
460
|
452
|
4.9%
|
3,805
|
141
|
170
|
4.5%
|
13,003
|
601
|
623
|
4.8%
|
Updated 1H25 figures for various regions and business lines. p. 13
| 1H25 Updated figures
|
|
|
|
|
|
|
|
|
|
|
Total i
|
| in Euro million
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
| France ii,iii
|
6,969
|
204
|
245
|
3.5%
|
3,261
|
—
|
82
|
2.5%
|
10,229
|
204
|
327
|
3.2%
|
| Europe iii
|
5,585
|
328
|
271
|
4.8%
|
2,109
|
83
|
76
|
3.6%
|
7,694
|
410
|
347
|
4.5%
|
| Asia, Africa & EME-LATAM
|
6,228
|
389
|
380
|
6.1%
|
1,120
|
140
|
120
|
10.7%
|
7,347
|
529
|
500
|
6.8%
|
| Transversal ii
|
153
|
12
|
8
|
5.2%
|
—
|
—
|
—
|
—
|
153
|
12
|
8
|
5.2%
|
| Total
|
18,934
|
934
|
904
|
4.8%
|
6,490
|
223
|
278
|
4.3%
|
25,424
|
1,156
|
1,182
|
4.6%
|
Updated 9M25 figures for various regions and business lines. p. 13
| 9M25 Updated figures
|
|
|
Life
|
|
|
|
|
Total i
|
| in Euro million
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
PVEP
|
NB CSM (pre-tax)
|
NBV (post-tax)
|
NBV margin (%)
|
| France ii,iii
|
9,911
|
277
|
344
|
3.5%
|
4,788
|
—
|
116
|
2.4%
|
14,698
|
277
|
459
|
3.1%
|
| Europe iii
|
7,900
|
450
|
365
|
4.6%
|
3,215
|
114
|
104
|
3.2%
|
11,115
|
564
|
469
|
4.2%
|
| Asia, Africa & EME-LATAM
|
9,408
|
600
|
592
|
6.3%
|
1,502
|
199
|
167
|
11.1%
|
10,910
|
799
|
759
|
7.0%
|
| Transversal ii
|
230
|
18
|
12
|
5.2%
|
—
|
—
|
—
|
—
|
230
|
18
|
12
|
5.2%
|
| Total
|
27,448
|
1,345
|
1,312
|
4.8%
|
9,505
|
313
|
387
|
4.1%
|
36,953
|
1,659
|
1,698
|
4.6%
|
NB CSM to NBV breakdown for 1Q25 updated figures. p. 13
| NB CSM to NBV 1Q25 Updated figures
|
NB CSM to NBV 1Q25 Updated figures
|
NB CSM to NBV 1Q25 Updated figures
|
NB CSM to NBV 1Q25 Updated figures
|
| NB CSM (pre-tax)
|
460
|
141
|
601
|
| Other NBV(pre-tax)
|
133
|
82
|
215
|
| Tax
|
-141
|
-53
|
-194
|
| Total NBV
|
452
|
170
|
623
|
NB CSM to NBV breakdown for 1H25 updated figures. p. 13
| 1H25 Updated figures NB CSM to NBV
|
1H25 Updated figures NB CSM to NBV
|
1H25 Updated figures NB CSM to NBV
|
1H25 Updated figures NB CSM to NBV
|
| NB CSM (pre-tax)
|
934
|
223
|
1,156
|
| Other NBV(pre-tax)
|
258
|
144
|
402
|
| Tax
|
-288
|
-89
|
-377
|
| Total NBV
|
904
|
278
|
1,182
|
NB CSM to NBV breakdown for 9M25 updated figures. p. 13
| NB CSM to NBV 9M25 Updated figures
|
NB CSM to NBV 9M25 Updated figures
|
NB CSM to NBV 9M25 Updated figures
|
NB CSM to NBV 9M25 Updated figures
|
| NB CSM (pre-tax)
|
1,345
|
313
|
1,659
|
| Other NBV(pre-tax)
|
384
|
198
|
583
|
| Tax
|
-418
|
-125
|
-543
|
| Total NBV
|
1,312
|
387
|
1,698
|
- Changes are compared to 1Q25 updated figures based on FY25 financial and actuarial assumptions p. 14.
Life and Health new business metrics by region for 1Q26. p. 14
|
|
Life New Business Metrics 1Q26
|
Health i New Business Metrics 1Q26
|
Total i New Business Metrics 1Q26
|
| in Euro million
|
PVEP
|
Change ii
|
NB CSM (pre-tax)
|
Change
|
NBV (post-tax)
|
Change ii
|
NBV margin (%)
|
Change ii
|
PVEP
|
Change
|
ii NB CSM (pre-tax)
|
Change ii
|
NBV (post-tax) Change
|
NBV margin (%)
|
Change ii
|
PVEP
|
Change ii
|
NB CSM (pre-tax)
|
Change ii
|
NBV (post-tax)
|
Change ii
|
NBV margin (%)
|
Change ii
|
| France iii,iv
|
3,348
|
+11%
|
96
|
+2%
|
112
|
+8%
|
3.3%
|
-0.1 pt
|
1,815
|
+16%
|
—
|
—
|
46 +5%
|
2.5%
|
-0.3 pt
|
5,162
|
+12%
|
96
|
+2%
|
158
|
+7%
|
3.1%
|
-0.1 pt
|
| Europe iv
|
3,287
|
+8%
|
187
|
-1%
|
156
|
-5%
|
4.8%
|
-0.7 pt
|
—
|
1,707 +4%
|
89
|
+17%
|
77 +15%
|
4.5%
|
+0.4 pt
|
4,994
|
+7%
|
275
|
+4%
|
233
|
0%
|
4.7%
|
-0.3 pt
|
| Asia, Africa & EME-LATAM
|
3,129
|
+11%
|
178
|
+13%
|
178
|
+7%
|
5.7%
|
-0.2 pt
|
—
|
407 -26%
|
46
|
-22%
|
37 -32%
|
9.1%
|
-0.8 pt
|
3,536
|
+5%
|
224
|
+4%
|
215
|
-2%
|
6.1%
|
-0.5 pt
|
| Transversal iii
|
67
|
+7%
|
5
|
+7%
|
3
|
+7%
|
5.2%
|
0.0 pt
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
67
|
+7%
|
5
|
+7% 3
|
—
|
+7%
|
5.2%
|
0.0 pt
|
| Total
|
9,831
|
+10%
|
466
|
+5%
|
450
|
+3%
|
4.6%
|
-0.3 pt
|
3,929
|
+4%
|
135
|
-1%
|
160 -4%
|
4.1%
|
-0.4 pt
|
13,760
|
+8%
|
601
|
+4%
|
609
|
+1%
|
4.4%
|
-0.3 pt
|
NB CSM to NBV breakdown for 1Q26. p. 14
| NB CSM to NBV
|
NB CSM to NBV
|
NB CSM to NBV
|
NB CSM to NBV
|
| NB CSM (pre-tax)
|
466
|
135
|
601
|
| Other NBV(pre-tax)
|
125
|
73
|
198
|
| Tax
|
-142
|
-48
|
-190
|
| NBV
|
450
|
160
|
609
|
Net flows by business line
Net flows by business line for 1Q25 and 1Q26. p. 15
| in Euro billion
|
1Q25
|
1Q26
|
| Health i
|
+0.8
|
+1.0
|
| Protection
|
+1.8
|
+1.8
|
| G/A Savings
|
-0.7
|
-0.8
|
Net flows for capital light and traditional G/A for 1Q25 and 1Q26. p. 15
| o/w capital light ii
|
+0.6
|
+0.7
|
| o/w traditional G/A
|
-1.3
|
-1.5
|
Total Life & Health net flows, including Unit-Linked, for 1Q25 and 1Q26. p. 15
| Unit-Linked iii
|
+0.5
|
+0.7
|
| Total Life & Health i net flows
|
+2.5
|
+2.7
|
- Health business written predominantly in Life entities is included p. 15.
- Capital light G/A encompasses products with no guarantees, guarantees at maturity only, or guarantees equal to or lower than 0% p. 15.
- Investment contracts with no discretionary participation features ('DPF') are included p. 15.
- On February 27, 2026, AXA announced the execution of a share repurchase agreement for its share buyback program of up to EUR 1.25bn p. 16.
- The HY26 Earnings Release is scheduled for July 31, 2026 p. 16.
- AXA Investor Day is scheduled for September 15, 2026 p. 16.
- An AXA Investor roundtable on the strategy for AXA key markets is scheduled for September 21, 2026 p. 16.
- 9M26 Activity Indicators are scheduled for October 29, 2026 p. 16.